Automated Data Exploration.
AutoDiscovery is an intelligent automated exploratory data analysis software that helps biomed researchers unveiling complex relationships hidden in the data files of scientific experiments and clinical trials.
Pharma companies, hospitals and universities are already using our technology.
Try out our technology for free or let us deal with your data for a proof of concept.
From data consolidation to exploration of results in less than 10 clics.
AutoDiscovery uses traditional statistical methods and standard Excel files.
Unveil high potential (exploratory) and significance (confirmatory) associations.
5 Reasons To Use AutoDiscovery
AutoDiscovery is targeted to Principal Investigators with very little time for data analysis and limited statistical knowledge focused on productive, high impact research.
Cause-effect potential, false discovery rates, small-complex data, groups and treatments and traceability of results are common biomed research needs specifically covered by AutoDiscovery
AutoDiscovery automatically evaluates the proper statistical tests to assess the relationships between every combination of variables at every individual subset of your data.
x10 times faster, x200 times wider analysis.
Smart Exhaustivity
Biomed-Specific
PI-Convenient
What's In It For Me?
Customers & Collaborators
For Researchers. By Researchers.
Anatomic Pathology. Uveal Melanoma.
A Fruitful Collaboration >>
One of the goals of this study was to assess how the immunohisto-chemical expression of the markers that are part of the signaling act as independent predictors of the risk of metastasis or variables of global survival.
Microbiology.
A Fruitful Collaboration >>
The main objective was to evaluate the potential relationships between clinical/epidemiological data and genetical microbial features in a cohort of patients under mechanical ventilation and isolation of Staphylococcus aureus in the respiratory tract.
Butler Scientifics is a proud member of Advance(CAT) platform which gathers the efforts and expertise of 18 catalan institutions, both public and private, to speed up the conversion of advanced therapies from the idea to the product.
This work has been developed with the support of ACCIÓ (Agència per la Competitivitat de l'Empresa; Generalitat de Catalunya) under the Catalonian ERDF operational program (European Regional Development Fund) 2014-2020.
